Clinical Trial Update: Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy [Phase 2]

View source ↗

Summary

Completion of a Phase 2 trial evaluating melatonin as a circadian regulator, neuromodulator, and myelo-protector in adjuvant breast cancer chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: Sleep Disorders, Circadian Rhythm, Depression | Phase 2 | Status: COMPLETED